Waters Corporation (WAT) reported its financial results for Q1 2021 and Q4 2025, also completing its strategic merger with BD's diagnostic solutions, making a substantial addition to its offerings. Notably, WAT achieved the highest daily trading volume of $270 million, accompanied by an earnings outlook adjustment. An FDA clearance of a comprehensive at-home cervical cancer screening tool, the Onclarity HPV Self-Collection Kit, was announced, regarded as a game-changer for cervical cancer cases. There was a share slide post the Q4 earnings report. The stock dropped more than 10% on deal-close day with BD business arriving softer than modeled. Waters Corp. faced shareholder suits over the $17.5B merger with BD. Freeing up to $3.5B via a senior notes offering, a drop of 3.79% in trading on Mar 30 was observed. New stock options and RSUs were awarded to WAT CEO, hinting at the company's confidence in its future performance. Finally, the deal with Becton Dickinson Unit is deemed a long-term play filled with risks for Waters Corp.
Waters Corp WAT News Analytics from Thu, 10 Jul 2025 07:00:00 GMT to Sat, 11 Apr 2026 06:37:38 GMT -
Rating 7
- Innovation -5
- Information 6
- Rumor -2
